Cargando…
De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories
Isoflavonoids comprise a class of plant natural products with great nutraceutical, pharmaceutical and agricultural significance. Their low abundance in nature and structural complexity however hampers access to these phytochemicals through traditional crop-based manufacturing or chemical synthesis....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526750/ https://www.ncbi.nlm.nih.gov/pubmed/34667183 http://dx.doi.org/10.1038/s41467-021-26361-1 |
_version_ | 1784585928689319936 |
---|---|
author | Liu, Quanli Liu, Yi Li, Gang Savolainen, Otto Chen, Yun Nielsen, Jens |
author_facet | Liu, Quanli Liu, Yi Li, Gang Savolainen, Otto Chen, Yun Nielsen, Jens |
author_sort | Liu, Quanli |
collection | PubMed |
description | Isoflavonoids comprise a class of plant natural products with great nutraceutical, pharmaceutical and agricultural significance. Their low abundance in nature and structural complexity however hampers access to these phytochemicals through traditional crop-based manufacturing or chemical synthesis. Microbial bioproduction therefore represents an attractive alternative. Here, we engineer the metabolism of Saccharomyces cerevisiae to become a platform for efficient production of daidzein, a core chemical scaffold for isoflavonoid biosynthesis, and demonstrate its application towards producing bioactive glucosides from glucose, following the screening-reconstruction-application engineering framework. First, we rebuild daidzein biosynthesis in yeast and its production is then improved by 94-fold through screening biosynthetic enzymes, identifying rate-limiting steps, implementing dynamic control, engineering substrate trafficking and fine-tuning competing metabolic processes. The optimized strain produces up to 85.4 mg L(−1) of daidzein and introducing plant glycosyltransferases in this strain results in production of bioactive puerarin (72.8 mg L(−1)) and daidzin (73.2 mg L(−1)). Our work provides a promising step towards developing synthetic yeast cell factories for de novo biosynthesis of value-added isoflavonoids and the multi-phased framework may be extended to engineer pathways of complex natural products in other microbial hosts. |
format | Online Article Text |
id | pubmed-8526750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-85267502021-11-15 De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories Liu, Quanli Liu, Yi Li, Gang Savolainen, Otto Chen, Yun Nielsen, Jens Nat Commun Article Isoflavonoids comprise a class of plant natural products with great nutraceutical, pharmaceutical and agricultural significance. Their low abundance in nature and structural complexity however hampers access to these phytochemicals through traditional crop-based manufacturing or chemical synthesis. Microbial bioproduction therefore represents an attractive alternative. Here, we engineer the metabolism of Saccharomyces cerevisiae to become a platform for efficient production of daidzein, a core chemical scaffold for isoflavonoid biosynthesis, and demonstrate its application towards producing bioactive glucosides from glucose, following the screening-reconstruction-application engineering framework. First, we rebuild daidzein biosynthesis in yeast and its production is then improved by 94-fold through screening biosynthetic enzymes, identifying rate-limiting steps, implementing dynamic control, engineering substrate trafficking and fine-tuning competing metabolic processes. The optimized strain produces up to 85.4 mg L(−1) of daidzein and introducing plant glycosyltransferases in this strain results in production of bioactive puerarin (72.8 mg L(−1)) and daidzin (73.2 mg L(−1)). Our work provides a promising step towards developing synthetic yeast cell factories for de novo biosynthesis of value-added isoflavonoids and the multi-phased framework may be extended to engineer pathways of complex natural products in other microbial hosts. Nature Publishing Group UK 2021-10-19 /pmc/articles/PMC8526750/ /pubmed/34667183 http://dx.doi.org/10.1038/s41467-021-26361-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Liu, Quanli Liu, Yi Li, Gang Savolainen, Otto Chen, Yun Nielsen, Jens De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories |
title | De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories |
title_full | De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories |
title_fullStr | De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories |
title_full_unstemmed | De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories |
title_short | De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories |
title_sort | de novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526750/ https://www.ncbi.nlm.nih.gov/pubmed/34667183 http://dx.doi.org/10.1038/s41467-021-26361-1 |
work_keys_str_mv | AT liuquanli denovobiosynthesisofbioactiveisoflavonoidsbyengineeredyeastcellfactories AT liuyi denovobiosynthesisofbioactiveisoflavonoidsbyengineeredyeastcellfactories AT ligang denovobiosynthesisofbioactiveisoflavonoidsbyengineeredyeastcellfactories AT savolainenotto denovobiosynthesisofbioactiveisoflavonoidsbyengineeredyeastcellfactories AT chenyun denovobiosynthesisofbioactiveisoflavonoidsbyengineeredyeastcellfactories AT nielsenjens denovobiosynthesisofbioactiveisoflavonoidsbyengineeredyeastcellfactories |